
Intervacc Investor Relations Material
Latest events

Q3 2024
Intervacc
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Intervacc
Access all reports
Intervacc AB, a biotechnology company, engages in the research and development of veterinary vaccines using recombinant proteins for animal health. The company offers Canvax, a vaccine for bovine viral diarrhea; and Fervac B, a vaccine for feline viral rhinotracheitis, calicivirus, and panleukopenia. It also provides a range of potential prevention vaccines to veterinarians, including vaccines to control rabies. Intervacc is based in Hägersten, Sweden.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
IVACC
Country
🇸🇪 Sweden